Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its comprehensive product line features treatments such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was established in 1987 by Ronald M. Evans and is headquartered in Jupiter, Florida.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of LGND is 370 and suggests 20% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas